• 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
  • 2
    Kendler KS,MacLean C,Neale M,Kessler R,Heath A,Eaves L. The genetic epidemiology of bulimia nervosa. Am J Psychiatry 1991; 148: 16271637.
  • 3
    Berrettini W. Genetics of psychiatric disease. Annu Rev Med 2000; 51: 465479.
  • 4
    Bulik C,Sullivan PF,Tozzi F,Furberg H,Lichtenstein P,Pedersen NL. Prevalence, heritability and prospective risk factors for anorexia nervosa. Arch Gen Psychiatry 2006; 63: 305312.
  • 5
    Wagner A,Barbarich N,Frank G,Bailer U,Weissfeld L,Henry S, et al. Personality traits after recovery from eating disorders: Do subtypes differ? Int J Eat Disord 2006; 39: 276284.
  • 6
    Klump K,Strober M,Johnson C,Thornton L,Bulik C,Devlin B, et al. Personality characteristics of women before and after recovery from an eating disorder. Psych Med 2004; 34: 14071418.
  • 7
    Lilenfeld L,Wonderlich S,Riso LP,Crosby R,Mitchell J. Eating disorders and personality: A methodological and empirical review. Clin Psychol Rev 2006; 26: 299320.
  • 8
    Bulik C,Tozzi F,Anderson C,Mazzeo S,Aggen S,Sullivan P. The relation between eating disorders and components of perfectionism. Am J Psychiatry 2003; 160: 366368.
  • 9
    Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008; 94: 121135.
  • 10
    Halford J,Cooper G,Dovey T. The pharmacology of human appetite expression. Curr Drug Targets 2004; 5: 221240.
  • 11
    Volkow ND,Wang G,Fowler J,Logan j,Jayne M,Franceschi D, et al. “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylephenidate amplifies this effect. Synapse 2002; 44: 175180.
  • 12
    Bergen A,Yeager M,Welch R,Haque K,Ganjei JK,Mazzanti C, et al. Association of multiple DRD2 polymorphisms with anorexia nervosa. Neuropsychopharm 2005; 30: 17031710.
  • 13
    Lawrence A. Impaired visual discrimination learning in anorexia nervosa. Appetite 2003; 20: 8589.
  • 14
    Friederich HC,Kumari V,Uher R,Riga M,Schmidt U,Campbell IC, et al. Differential motivational responses to food and pleasurable cues in anorexia and bulimia nervosa: A startle reflex paradigm. Psychol Med 2006; 36: 13271335.
  • 15
    Kaye WH,Frank GK,McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharm 1999; 21: 503506.
  • 16
    Frank G,Bailer UF,Henry S,Drevets W,Meltzer CC,Price JC, et al. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11C]raclopride. Biol Psychiatry 2005; 58: 908912.
  • 17
    Bailer UF,Frank GK,Price JC,Meltzer CC,Becker CR,Mathis CA, Wagner A, et al. Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa (submitted).
  • 18
    Delgado M,Nystrom L,Fissel C,Noll D,Fiez J. Tracking the hemodynamic responses to reward and punishment in the striatum. J Neurophysiol 2000; 84: 30723077.
  • 19
    Montague R,Hyman S,Cohen J. Computational roles for dopamine in behavioural control. Nature 2004; 431: 760767.
  • 20
    Schultz W. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. Science 2004; 14: 139147.
  • 21
    Breier A,Su TP,Saunders R,Carson RE,Kolachana BS,de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 25692574.
  • 22
    Laruelle M,Iyer R,Al-Tikriti M,Zea-Ponce Y,Malison R,Zoghbi S. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25: 114.
  • 23
    Martinez D,Gil R,Slifstein M,Hwang D,Huang Y,Perez A, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005; 58: 779786.
  • 24
    Martinez D,Slifstein M,Broft A,Mawlawi O,Hwang D,Huang Y, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285300.
  • 25
    Frank GK,Kaye WH,Meltzer CC,Price JC,Greer P,McConaha C, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biol Psychiatry 2002; 52: 896906.
  • 26
    Bailer UF,Price JC,Meltzer CC,Mathis CA,Frank GK,Weissfeld L, et al. Altered 5-HT2A receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology 2004; 29: 11431155.
  • 27
    Bailer UF,Frank GK,Henry SE,Price JC,Meltzer CC,Weissfeld L, et al. Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11C]WAY100635. Arch Gen Psychiatry 2005; 62: 10321041.
  • 28
    Bailer UF,Frank G,Henry S,Price J,Meltzer C,Mathis C, et al. Exaggerated 5-HT1A but normal 5-HT2A receptor activity in individuals ill with anorexia nervosa. Biol Psychiatry 2007; 61: 10901099.
  • 29
    Bailer UF,Frank G,Henry S,Price J,Meltzer CC,Becker C, et al. Serotonin transporter binding after recovery from eating disorders. Psychopharmacology 2007; 195: 315324.
  • 30
    Halldin C,Farde L,Hogberg T,Hall H,Strom P,Solin O. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Int J Rad App Instrum B. 1991; 18: 871881.
  • 31
    Innis R,Cunningham V,Delforge J,Fujita M,Gjedde A,Gunn R, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 15331539.
  • 32
    Narendran R,Frankle W,Mason N,Laymon C,Lopresti B,Price C, et al. Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [C]-N-propyl-norapomorphine: Preliminary evaluation and reproducibility studies. Synapse. 2009; 63: 574584.
  • 33
    Narendran R,Mason N,Laymon C,Lopresti B,Velasquez N,May M, et al. A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010; 333: 533539.
  • 34
    Mawlawi O,Martinez D,Slifstein M,Broft A,Chatterjee R,Hwang D, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 10341057.
  • 35
    Riccardi P,Li E,Ansari M,Zald D,Park S,Dawant B, et al. Riccardi P,Li E,Ansari M,Zald D,Park S,Dawant B,Anderson S,Doop M,Woodward N,Schoenberg E,Schmitt D,Baldwin R,Kessler RC. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharm 2005; 31: 10161026.
  • 36
    Wolkin A,Angrist B,Wolf AP,Brodie J,Wolkin B,Jaeger J, et al. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology. 1987; 92: 241246.
  • 37
    Wolkin A,Sanfilipo M,Angrist B,Duncan E,Wieland S,Wolf A, et al. Acute d-amphetamine challenge in schozophrenia: effects on cerebral glucose utilization and clinical symptomatology. Psychol Med 1994; 35: 649657.
  • 38
    Willeit M,Ginovart N,Graff A,Rusjan P,Vitcu I,Houle S, et al. First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharm 2008; 33: 279289.
  • 39
    Swerdlow N,Eastvold A,Karban B,Ploum Y,Stephany N,Geyer M, et al. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: Time course studies. Psychopharm (Berl) 2002; 161: 189201.
  • 40
    Lammertsma AA,Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4(3 Part 1): 153158.
  • 41
    Cohen J. Statistical Power Analysis for Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc, 1988.
  • 42
    Laruelle M,Abi-Dargham A,Van Dyck C,Rosenblatt W,Zea-Ponce Y,Zoghbi S, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995; 36: 11821190.
  • 43
    Volkow N,Wang G,Fowler J,Logan J,Gatley S,Wong C, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291: 409415.
  • 44
    Drevets W,Gautier C,Price J,Kupfer D,Kinahan P,Grace A, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 8196.
  • 45
    Brauer L,de Wit H. Subjective responses to D-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psych 1996; 39: 2631.
  • 46
    de Wit H,Uhlenhuth E,Johanson C. Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 1986; 16: 341360.
  • 47
    Gabbay F. Variations in affect following amphetamine and placebo: Markers of stimulant drug preference. Exp Clin Psychopharmacol 2003; 11: 91101.
  • 48
    Mitchell S,Laurent C,de Wit H. Interaction of expectancy and the pharmacological effects of D-amphetamine: Subjective effects and self-administration. Psychopharm (Berl) 1996; 125: 371378.
  • 49
    Hutchinson K,Wood M,Swift R. Personality factors moderate subjective and psychophysiological responses to D-amphetamine in humans. Exp Clin Psychopharmacol 1999; 7: 493501.
  • 50
    White TJ,de Wit H. Differential subjective effects of D-amphetamine by gender,hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 2002; 73: 729741.
  • 51
    Wagner A,Aizenstein H,Venkatraman M,Fudge J,May J,Mazurkewicz L, et al. Altered reward processing in women recovered from anorexia nervosa. Am J Psych 2007; 164: 18421849.
  • 52
    Kaye WH,Barbarich NC,Putnam K,Gendall KA,Fernstrom J,Fernstrom M, et al. Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. Int J Eat Disord 2003; 33: 257267.
  • 53
    Strober M. Family-genetic perspectives on anorexia nervosa and bulimia nervosa. In: Brownell K,Fairburn C, editors. Eating Disorders and Obesity-A Comprehensive Handbook. New York: The Guilford Press, 1995, pp. 212218.
  • 54
    Vitousek K,Manke F. Personality variables and disorders in anorexia nervosa and bulimia nervosa. J Abnorm Psychol 1994; 103: 137147.
  • 55
    Bassareo V,Di Chiara G. Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments. Neuroscience 1999; 89: 637641.
  • 56
    Bissada H,Tasca G,Barber A,Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psych 2008; 165: 12811288.
  • 57
    Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998; 80: 127.
  • 58
    Schott B,Muinuzzi L,Krebs R,Elmenhorst D,Lang M,Winz O, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neuroscience 2008; 28: 1431114319.
  • 59
    Zastrow A,Kaiser SS,Stippich C,Walther S,Herzog W,Tchanturia K,Belger A, et al. Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa. Am J Psychiatry 2009; 166: 608616.
  • 60
    Drevets WC,Price JC,Kupfer DJ,Kinahan PE,Lopresti B,Holt D, et al. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 1999; 21: 694709.
  • 61
    Leyton M,Boileau I,Benkelfat C,Diksic M,Baker G,Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: A PET/[11C]raclopride study in healthy men. Neuropsychopharmacology. 2002; 27: 10271035.
  • 62
    Floresco S,Tse M,Ghods-Sharifi S. Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharm 2008; 33: 19661979.